Ono Pharmaceutical Co., Ltd.
OPHLY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | -0.03 | 0.20 | -1.15 |
| FCF Yield | 6.41% | 0.15% | 5.08% | 0.01% |
| EV / EBITDA | 18.33 | 23.19 | -117.73 | 31.82 |
| Quality | ||||
| ROIC | 2.37% | 1.85% | -0.58% | 1.28% |
| Gross Margin | 73.02% | 70.98% | 59.72% | 65.85% |
| Cash Conversion Ratio | 2.31 | 0.19 | -5.96 | 0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.48% | 2.56% | 2.87% | 4.35% |
| Free Cash Flow Growth | -69.61% | -97.01% | 68,629.25% | -99.83% |
| Safety | ||||
| Net Debt / EBITDA | -1.29 | -0.03 | 10.00 | -0.28 |
| Interest Coverage | 24.29 | 0.00 | -6.03 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.51 | 0.52 | 0.60 | 0.59 |
| Cash Conversion Cycle | 106.26 | 119.82 | 79.42 | 134.45 |